Michael Julius

Read how they describe their research on their University of Toronto profile.

• VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses

  JCI Insight · 2017

• Lck-dependent Fyn Activation Requires C Terminus-dependent Targeting of Kinase-active Lck to Lipid Rafts

  Journal of Biological Chemistry · 2008 · senior author

• Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells.

  Proceedings of the National Academy of Sciences of the United States of America · 2007

• Intellectual Property Mobilization 2005 Competition - Medical Technologies Research and Commercialization Collaborative (Sunnybrook and Women's College Health Sciences Centre), Group Application

  NSERC · 2005 · Co-investigator

  $191,000